Opening Hours : Monday to Friday - 8am to 5pm

IVERMECTIN
FOR COVID-19 TRIALS

RANDOMISED CONTROLLED TRIALS FOR THE REPURPOSING OF IVERMECTIN FOR USE IN COVID 19

explore

IVERMECTIN FOR
COVID-19 TRIALS

RANDOMISED CONTROLLED TRIALS FOR THE REPURPOSING OF IVERMECTIN FOR USE IN COVID 19

explore

IVERMECTIN
FOR COVID-19 TRIALS

RANDOMISED CONTROLLED TRIALS FOR THE REPURPOSING OF IVERMECTIN FOR USE IN COVID 19

explore

IVERCOVID RESEARCH
STUDY

A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL ASSESSING THE EFFICACY AND SAFETY OF IVERMECTIN IN COVID- 19 (IVERCOVID) STUDY

STATEMENT
OF COMPLIANCE

This document is a protocol for a clinical research study. The study will be conducted in compliance with all stipulations of this protocol, the conditions of ethics committee approval, the NHMRC National Statement on Ethical Conduct in Human Research (2007) and the Note for Guidance on Good Clinical Practice (CPMP/ICH-135/95).

Details
The current Covid 19 pandemic has infected 22 million people worldwide with 760,000 deaths. In Nigeria, it has affected 50,000 people with 1000 deaths. The international epicenters are USA, India and Brazil while the epicenter in Nigeria are Abuja and Lagos. Beyond supportive therapy, there is no specific universally accepted treatment and there are currently about 150 candidate vaccines some of which are already in phase 3 testing.
Researchers in Lagos, Abuja and diaspora Nigerians have been putting heads together and have come up with certain lines of research which we would like to commend to the Presidential Task Force for funding consideration. There are two intertwined lines of research that we are considering at the moment ....
Explore More

  • •     Background and study aims:
  • Ivermectin is a drug that has been in use for over three decades for the treatment of River blindness in Africa. Recently studies in Australia suggest that it is very active In vitro (in laboratory conditions) in eliminating the COVID-19 RNA virus, reducing viral loads by a factor of 5000. Our study is aimed at determining if Ivermectin is equally effective in-vivo (in infected human beings) and if so, is it safe, and what are the optimal doses? We will also be interested to know at what phase of the illness it is most useful- as prevention, in the early phase of the illness, or in the late stages. If it is found to be effective, it could be a game changer in how sick people are treated, essentially with two to six tablets, or even in how populations are prevented from the disease
Explore More

  •     Ivermectin has shown evidence of efficacy beyond Remdesivir, the touted American Antiviral drug, but we cannot prove it or deploy it in Nigeria or anywhere else until this research is undertaken. Unlike the Madagascar solution, which is essentially a concoction of native herbs (even if efficacious), Ivermectin will be proven through this Randomised Control Trial, the highest standard of the proving of efficacy of medications accepted Internationally and by the American FDA. Nor do we have to wait for WHO to come and conduct research for us here. Ivermectin has been used in Nigeria over the past thirty years to treat River blindness. More Nigerians have used the drug than any other country in the world. It is ‘our’ drug, proven and safe in onchocerciasis. Why should outsiders tell us what to do?

Explore More

PRINCIPAL INVESTIGATOR


service-image

B.Sc. (Ife);MB.Chb; FWACS;FMCO;M.Sc.Epid(LSHTM)

The MD and Chief Consultant Rachel Eye Center, Prof. Olufemi .E. Babalola has over twenty years experience as a world class ophthalmic surgeon.

PROFESSOR OLUFEMI E BABALOLA

Performing procedures such including cataracts, glaucoma surgery, squints, plastic eye surgery corneal surgery and retinal detachment surgery. He is recognised by the Ophthalmological societies across the world and is President of the Nigerian Ophthalmological Society. He was trained at the University of Ife (BSc health sciences, MbChb), the ABU hospital , Queens Royal hospital Belfast UK, Aravind Eye Hospital, Madurai, India. He is a fellow of the West African College of Surgeons and the Nigerian Post graduate Medical College (FWACS, FMCophth). He is at present undergoing further training in Epidemiology at the University of London (MSc Epid). He has research interests in Onchocerciasis, Trachoma and sickle cell eye disease, and in tropical ophthalmology in general. He is widely published in these areas.
Professor Olufemi Babalola is the current president of Nigeria Guild of Medical Directors

service-image

B.Sc. (Ife);MB.Chb; FWACS; FMCS

Renowned Paediatric Surgeon with a special interest in neonatal oesophageal surgery and paediatric penile reconstruction. Professor Bode is a renowned Paediatric Surgeon who hails from Ejigbo, Osun state. He obtained his MBCHB at the University of Ife (then Obafemi Awolowo University) in 1980 and trained as a surgeon in LUTH from 1982-1990.

PROFESSOR CHRISTOPHER BODE

He became a Fellow of the West African College of Surgeons as well as Fellow of the National Postgraduate Medical College of Nigeria in 1992. He won many travel grants and awards, including the Sir Samuel Manuwa Memorial Award for overall best candidate at the finals of the NPMCN examinations in 1992. He also trained in paediatric laparoscopy at the Schneider Children’s Hospital, Tel Aviv, Israel and has had surgical training opportunities at the Manchester Children’s Hospital UK. Bode joined the College of Medicine of the University of Lagos in November 1992 as a lecturer and was Honorary Consultant Paediatric Surgeon to LUTH, with special interest in neonatal oesophageal surgery and paediatric penile reconstruction. He rose to become Professor of Surgery in 2010 and served LUTH as SERVCOM Nodal Officer from 2008-2012 and as Chairman, Medical Advisory Committee from 2012-14. Bode was Secretary General of the West African College of Surgeons from 2001-2007 and Treasurer, Pan African Association of Surgeons (PAAS) among others.

service-image

B.Sc;MB.Chb;FWACP;PhD(Pharmacol)
Adjunct Prof Baylor College, Texas,USA
Adesuyi Leslie was born on May 29, 1958, in Ibadan, Oyo State, Nigeria. Came to the United States, 1992. Son of Alexander Olu and Adeline Olu (Adeyemi) Ajayi. Bachelor of Science (BSc Hons) University Ife, Nigeria, 1977. Bachelor of Medicine, Bachelor of Surgery (MB, ChB), University Ife, Nigeria, 1980. Doctor of Philosophy (Ph.D.) University of Glasgow (Scotland) 1985. Fellowship of the West African College of Physicians (FWACP) Internal Medicine and Cardiology chapter.-1989.

PROFESSOR ADESUYI AJAYI

Head of Department of Medicine, Obafemi Awolowo University, Ile-Ife, Nigeria. Course Coordinator/ Editor, Cardiology Update Course, West African College of Physicians. Associate Editor, Nigeria Medical Journal Senior Scientist and Visiting Professor, Center for Cardiovascular Diseases, Texas Southern University, Houston Adjunct Professor of Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas. Member, Faculty Academic Senate, Chicago State University, Chicago Illinois Member, University Personnel Committee, Chicago State University, Chicago, Illinois Fellow, British Pharmacological Society ( FBPharmacolS) Member, International Order of Merit, International Biographical Center, Cambridge, UK Wellcome Trust Fellow in clinical science The Outstanding Young Person (TOYP) of Nigeria for academic accomplishments -Junior Chamber International Merck Fellow in Clinical Pharmacology Young Investigator Award recipient , American Society for Clinical Investigation Head of Department of Medicine, Obafemi Awolowo University Teaching Hospitals Complex Vice -Dean, Faculty of Clinical Sciences ( Medical school), OAU Ile -ife Honorary Consulant Cardiologist and Clinical Pharmacologist. OAU teaching hospital, Ile -Ife Member, Drug Revolving Fund Committee of the teaching hospital Chairman, Hospital Formulary and Drugs and Therapeutics Committee

CO - INVESTIGATORS

The Study took place in the Isolation Unit of the Lagos University Teaching Hospital,
Idi Araba, Lagos, Nigeria.

Prof Ademuyiwa Adesoji
Department of Surgery, College of Medicine, University of Lagos. Lagos State, Nigeria.
Prof Omilabu Sunday

Department of Surgery, College of Medicine, University of Lagos, Lagos State, Nigeria.

Dr Akase Iorhen
Department of Medicine, Lagos University Teaching Hospital, Lagos State, Nigeria..
Prof Adeyemo Wasiu
Department of Oral and Maxillofacial Surgery, College of Medicine, University of Lagos, Lagos State, Nigeria.
Dr Alakaloko Felix
Department of Surgery, Lagos University Teaching Hospital, Lagos State, Nigeria.
Dr Otrofanowei Erere
Department of Medicine, Lagos University Teaching Hospital, Lagos State, Nigeria.

STATEMENT OF COMPLIANCE
Read OR Download Research Details Here

This document is a protocol for a clinical research study. The study will be conducted in compliance with all stipulations of this protocol,
the conditions of ethics committee approval, the NHMRC National Statement on Ethical Conduct in Human Research (2007)
and the Note for Guidance on Good Clinical Practice (CPMP/ICH-135/95).

Ms Word Format

read more

Power Point Format

read more

Interim Report

read more

[Main] PDF Format

read more

ivercovid latest result

read more

Ivercovid Manuscript

read more

PROTOCOL SYNOPSIS

Contact Us

For enquiry concerning this project, please send us email through the contact form

Location

Lagos University Teaching Hospital,
Idi-Araba, Lagos, Nigeria.

Phone

+ (234) - 0809 - 860 - 3395
+ (234) - 0809 - 860 - 3395

Email

Support@ivercovid.com
info@ivercovid.com